Targeted biopsy-only detection rates for Grade Group ≥2 were 38% with microultrasonography, 34% with MRI/US-fusion (P=0.003 for noninferiority), and 40% with microultrasonography/MRI (P<0.001 ...

NEW YORK. (KFSN) -- For decades, doctors have diagnosed prostate cancer using what's been called a 'blind' biopsy, removing and testing a dozen tiny tissue samples to see if cancer is present. Now ...

Among nearly 18,000 participants, 0.6% of men who underwent MRI-targeted biopsy alone were diagnosed with clinically insignificant prostate cancer (Gleason 3+3) compared with 1.2% of those in a ...

2.7 The Artemis fusion biopsy system (InnoMedicus Artemis) includes a semi-robotic mechanical arm and a mobile workstation. The system uses ProFuse radiology software for preparing MRI data for fusion ...

A team of UCLA expertshas introduced refinements to targeted biopsy of prostate cancer, greatly improving the ability to distinguish men who should have treatment from those who could defer.

TOPLINE: High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6% ...

With targeted MRI/ultrasound and the ARTEMIS 3D Semi-Robotic Prostate Fusion Biopsy System technology available at Palm Beach Gardens Medical Center, the urology team is able to better identify ...

The five-year lung cancer survival rate increased by 22 percent in the five years between 2015 to 2019. It currently stands at 26.6 percent across all racial and ethnic groups.

The researchers wanted to determine if high-resolution micro-ultrasonography-guided biopsy was better than MRI fusion-guided biopsy for detecting prostate cancer in a clinical setting. The study found ...

Targeted biopsy-only detection rates for Grade Group ≥2 were 38% with microultrasonography, 34% with MRI/US-fusion (P=0.003 for noninferiority), and 40% with microultrasonography/MRI (P<0.001 ...

3.5 The committee considered that adopting MRI fusion biopsy systems could prolong waiting time for prostate biopsies, and that this was not captured in the cost-effectiveness estimates. The clinical ...